Claims
- 1. A compound having the formula ##STR2## or a pharmaceutically acceptable salt thereof, wherein .DELTA.-Abu is dehydro-.alpha.-aminobutyric acid;
- .beta.HL is D-erythro-.beta.-Hydroxyleucine; and,
- X is .beta.-hydroxytryptophan, .beta.-ketotryptophan or dehydrotryptophan.
- 2. A compound in accordance with claim 1 wherein X is .beta.-hydroxy-tryptophan.
- 3. A compound in accordance with claim 1 wherein X is .beta.-keto-tryptophan.
- 4. A compound in accordance with claim 1 wherein X is dehydrotryptophan.
- 5. A compound, or a pharmaceutically acceptable salt thereof in accordance with claim 2, having the ultraviolet spectrum of FIG. 1, the infrared spectrum of FIG. 2, the 67.5 MHz carbon NMR spectrum of FIG. 3 and the 400 MHz proton NMR spectrum of FIG. 4.
- 6. A compound, or a pharmaceutically acceptable salt thereof in accordance with claim 3, having the ultraviolet spectrum of FIG. 5, the empirical formula C.sub.57 H.sub.83 N.sub.12 O.sub.16, the infrared spectrum of FIG. 6, the 67.5 MHz carbon NMR spectrum of FIG. 7 and the 400 MHz proton NMR spectra of FIGS. 8 and 9.
- 7. A compound, or a pharmaceutically acceptable salt thereof in accordance with claim 4, having the ultraviolet spectrum of FIG. 10, the empirical formula C.sub.57 H.sub.83 N.sub.12 O.sub.15, the infrared spectrum of FIG. 11, the 67.5 MHz carbon NMR spectrum of FIG. 12 and the 400 MHz proton NMR spectrum of FIG. 13.
Parent Case Info
This is a continuation-in-part of U.S. Ser. No. 310,118 filed Feb. 9, 1989, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4294754 |
Takahara et al. |
Oct 1981 |
|
4754018 |
Tymiak et al. |
Jun 1988 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
310118 |
Feb 1989 |
|